Synovics Pharmaceuticals, Inc.
Other OTCTotal Valuation
Synovics Pharmaceuticals, Inc. carries a market capitalization of 2,983.00, placing it among publicly traded companies globally. Its enterprise value stands at 5.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2,983.00 |
| Enterprise Value | 5.24M |
Share Statistics
Synovics Pharmaceuticals, Inc. currently has 28.94M shares outstanding.
| Shares Outstanding | 28.94M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 0.27 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 1.57 |
Financial Position
Synovics Pharmaceuticals, Inc. maintains a current ratio of 0.27, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -587.15, indicating conservative leverage, while an interest coverage ratio of -5.48 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.27 |
| Quick Ratio | 0.10 |
| Debt / Equity | -587.15 |
| Debt / EBITDA | -0.73 |
| Interest Coverage | -5.48 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -23.83 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 6.48 |
Stock Price Statistics
Synovics Pharmaceuticals, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Synovics Pharmaceuticals, Inc. generated 19.09M in revenue and converted that into -5.04M in net income, yielding earnings per share of -0.17. EBITDA reached -6.21M, while operating income came in at -4.32M.
| Revenue | 19.09M |
| Gross Profit | 4.47M |
| Operating Income | -4.32M |
| Pretax Income | -1.10M |
| Net Income | -5.04M |
| EBITDA | -6.21M |
| EBIT | -4.32M |
| Earnings Per Share (EPS) | -0.17 |
Balance Sheet
Synovics Pharmaceuticals, Inc. holds 129,860.00 in cash and equivalents against 4.54M in total debt, resulting in a net debt position of 4.01M. Total book value stands at -84.99M, with working capital of -12.87M providing operational flexibility.
| Cash & Cash Equivalents | 129,860.00 |
| Total Debt | 4.54M |
| Net Debt | 4.01M |
| Equity (Book Value) | -84.99M |
| Book Value Per Share | -2.93 |
| Working Capital | -12.87M |
Cash Flow
Synovics Pharmaceuticals, Inc. produced 1.99M in operating cash flow over the past twelve months. After subtracting -212,916.00 in capital expenditures, free cash flow totaled 1.77M - equivalent to 0.06 per share.
| Operating Cash Flow | 1.99M |
| Capital Expenditures | -212,916.00 |
| Free Cash Flow | 1.77M |
| FCF Per Share | 0.06 |
Margins
Synovics Pharmaceuticals, Inc. operates with a gross margin of 23.39, reflecting its pricing power and cost economics. The operating margin of -22.62 and net profit margin of -26.42 provide insight into operational efficiency.
| Gross Margin | 23.39 |
| Operating Margin | -22.62 |
| Pretax Margin | -5.77 |
| Profit Margin | -26.42 |
| EBITDA Margin | -32.54 |
Stock Splits
Synovics Pharmaceuticals, Inc.'s most recent stock split took place on May 30, 2001 with a 5:1 split ratio.
| Last Split Date | 5/30/2001 |
| Split Ratio | 5:1 |
Scores
Synovics Pharmaceuticals, Inc. posts an Altman Z-Score of -18.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -18.57 |